Try our beta test site

Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: August 18, 2011
Last updated: May 27, 2016
Last verified: May 2016
To confirm the safety of the long-term use of TORISEL 25 mg for Intravenous Drip Infusion particularly for the onset of interstitial lung disease from Weeks 25 to 96 after the start of administration.

Condition Intervention
Renal Cell Carcinoma
Drug: Temsirolimus

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Torisel 25mg For Intravenous Drip Infusion Special Investigation - Survey On Long-Term Use

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Response rate (Responsive cases: CR, PR, PD, SD) [ Time Frame: 96 weeks ]
  • The onset of interstitial lung disease in long-term use [ Time Frame: 96 weeks ]

Secondary Outcome Measures:
  • The incidence of adverse events in long-term use [ Time Frame: 96 weeks ]

Enrollment: 133
Study Start Date: September 2011
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Among the cases registered and treated in the Special Investigation, All-case Survey of temsirolimus, those continuously treated with temsirolimus for more than 24 weeks will be included.
Drug: Temsirolimus
The usual adult dosage of this drug is 25 mg as temsirolimus once weekly by intravenous drip infusion for 30 to 60 minutes. The dosage may be appropriately reduced, depending on patient condition.
Other Name: Torisel

Detailed Description:
Implemented as a Drug Use Investigation by Central Registration System

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).

Inclusion Criteria:

  • Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).
  • Among patients registered and treated in the Special Investigation, All-case Survey of Torisel, those continuously treated with Torisel for more than 24 weeks will be included.

Exclusion Criteria:

  • Patients not administered Torisel.
  • Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01420601

Kinki University Hospital
Osakasayama, Osaka, Japan, 589-8511
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT01420601     History of Changes
Other Study ID Numbers: B1771016
Study First Received: August 18, 2011
Last Updated: May 27, 2016

Keywords provided by Pfizer:
Long-term use
Regulatory Post Marketing Commitment Plan

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on March 30, 2017